Safety and Intranasal Retention of a Broad-Spectrum Anti-SARS-CoV-2 Monoclonal Antibody SA55 Nasal Spray in Healthy Volunteers: A Phase I Clinical Trial
This study demonstrated favorable safety and tolerability of the SA55 nasal spray in healthy volunteers, exhibited satisfactory neutralizing activity against Omicron variants intranasally, and indicated low systemic toxicity risk.
Authors
- Yunlong Cao (ORCID: https://orcid.org/0000-0001-5918-1078)
- Yaling Hu (ORCID: https://orcid.org/0000-0002-6976-459X)
- Yibo Zhou
- Chaoying Hu (ORCID: https://orcid.org/0000-0002-0116-4387)
- Jianhua Li (ORCID: https://orcid.org/0000-0002-9216-4699)
- Jinxia Chen (ORCID: https://orcid.org/0000-0001-8264-9759)
- Ronghua Jin (ORCID: https://orcid.org/0000-0001-7445-5188)
- Xing Meng (ORCID: https://orcid.org/0000-0002-5309-7681)
- X. Sunney Xie (ORCID: https://orcid.org/0000-0001-7714-9776)
- Zhifang Ying
Institutions
- Capital Medical University (CN)
- Peking University (CN)
- Sinovac Biotech (CN)
- National Institutes for Food and Drug Control (CN)
- Beijing Ditan Hospital (CN)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-12-31
- DOI
- https://doi.org/10.3390/pharmaceutics17010043
- Citations
- 5
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.95